H.C. Wainwright Reaffirms Buy Rating on Assembly Biosciences, Inc. (ASMB) Amid Promising Trial Data
Assembly Biosciences, Inc. (NASDAQ:ASMB) is one of the top long-term biotechnology stocks to buy. On October 14, H.C.
Assembly Biosciences Inc. (ASMB)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Farallon Capital Thomas Steyer | 1,604,590 | $44,094,133 | +31% | 0.2% |
| 2. | Paradigm Biocapital Advisors Senai Asefaw | 1,553,748 | $42,696,995 | +134% | 0.8% |
| 3. | Commodore Capital Egen Atkinson And Michael Kramarz | 1,415,000 | $38,884,200 | +42% | 2.32% |
| 4. | RA Capital Management Peter Kolchinsky | 1,020,410 | $28,040,867 | 0.24% | |
| 5. | Parkman Healthcare Partners Greg Martinez | 721,181 | $19,818,054 | +76% | 2.03% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.00 | 2,295,920 | $0.00 | 4,505,391 | 2025-08-08 | Filing | |
| $15.61 | 3,202 | $49,997.63 | 3,202 | 2024-12-30 | Filing | |
| $21.37 | 940,499 | $20,098,463.63 | 2,209,471 | 2024-12-19 | Filing | |
| $14.85 | 5,000 | $74,250.00 | 728,113 | 2024-11-25 | Filing | |
| $15.00 | 2,976 | $44,640.00 | 723,113 | 2024-11-25 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $23.25 | 29 | $674.25 | 14,560 | 2026-06-17 | Filing | |
| $27.49 | 16 | $439.84 | 11,089 | 2026-03-30 | Filing | |
| $26.65 | 312 | $8,314.86 | 11,105 | 2026-03-30 | Filing | |
| $27.49 | 9 | $247.41 | 37,477 | 2026-03-30 | Filing | |
| $26.65 | 188 | $5,010.24 | 37,486 | 2026-03-30 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,977,089 | $136,770,406 | 8.3% | |
| 2. | 766,819 | $21,072,187 | 0% | |
| 3. | 558,942 | $15,359,726 | 0% | |
| 4. | 280,424 | $7,707,832 | 0% | |
| 5. | 207,047 | $5,689,652 | 0.01% |
News See All
Top 8 Long-Term Biotechnology Stocks to Buy
Momentum in biotechnology stocks is accelerating after years of underperformance.
Assembly Bio’s (ASMB) HBV Drug Shows Strong Efficacy in Phase 1b Trial
Assembly Biosciences, Inc. (NASDAQ:ASMB) is one of the growth stocks that could double by 2027.
11 Growth Stocks That Could Double by 2027
The focus should be on growth stocks over value stocks, as volatility in the equity markets has subsided significantly.
Assembly Biosciences, Inc. (ASMB) Announces Key Leadership and Plan Changes
Assembly Biosciences, Inc. (NASDAQ:ASMB) is among the best growth stocks to invest in for the next 5 years. In the wake of its recent Annual Meeting of Stockholders, Assembly Biosciences, Inc.
15 Best Growth Stocks to Invest in for the Next 5 Years
Before making any decision, whether big or small, we instinctively weigh its long-term impact, and this is particularly true in the case of stocks.
10 Best Small-Cap Biotech Stocks Under $10 in 2021
We like healthcare and technology industries because of their above-average long-term growth prospects. Biotechnology is at the intersection of healthcare and technology.
5 Best Small-Cap Biotech Stocks Under $10 in 2021
Below we presented the list of 5 best small-cap biotech stocks under $10 in 2021.
Is ASMB A Good Stock To Buy Now According To Hedge Funds?
After several tireless days we have finished crunching the numbers from nearly 817 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed...
Is Assembly Biosciences Inc (ASMB) A Good Stock To Buy?
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 823 13F filings that hedge funds and well-known value investors are required to file by the SEC.
Hedge Fund Resource Center